

Topical Scalp Delivery & Optimization of Lead Molecule SH-14b via Domain Two State-Space Simulation

Targeting Follicular Androgen Receptors for Androgenic Alopecia via Localized Permeation and Minimal Systemic Flux

TARGET MOLECULE
SH-14b Lead

ROUTE
Topical Scalp

FRAMEWORK TARGET
Domain 2 ($\mathcal{D}_2$)

DOCUMENT ID
PUB-SH1-2026-V4

1. INTRODUCTION & LOCALIZED TOPOLOGICAL MAPPING

The preclinical development of **SH-1** and its optimized derivative **SH-14b** focuses on targeted non-steroidal androgen receptor (AR) antagonism at the hair follicle level to treat androgenic alopecia without systemic endocrine exposure. Rather than relying on systemic oral bioavailability, the state-space model in **Domain Two ($\mathcal{D}_2$)** evaluates localized cutaneous flux, stratum corneum partitioning, and deep follicular papilla accumulation.

The revised topical state vector within $\mathcal{D}_2$ is parameterized as:

$$\mathbf{s}_2^{\text{topical}}(t) = [\mathbf{r}_{\text{geom}}, \log P, \text{MW}, K_p, \Delta G_{\text{bind}}]^T \in \mathcal{D}_2$$

$$d\mathbf{s}_2 / dt = \mathbf{A}_2 \mathbf{s}_2 + \sum_{j \neq 2} \mathbf{K}_{2j} \mathbf{s}_j + \Xi \cdot \nabla_{\mathcal{N}}(\mathbf{s}_2)$$

Here, $\log P$ (2.2–2.8) and skin permeability K_p are constrained to maximize sebum partitioning and dermal papilla binding ($\Delta G_{\text{bind}} = -12.1$ kcal/mol), while restricting total systemic flux below 3.0%.

< 2.5%

SYSTEMIC FLUX

89.4%

FOLLICLE RETENTION

2.52

TARGET LOG P

SH-14b

TOPICAL LEAD

2. TOPICAL STATE-SPACE OPTIMIZATION ARCHITECTURE

The multi-objective cost function $J(\mathbf{s}_2)$ prioritizes localized hair follicle infundibulum accumulation while penalizing dermal capillary bed entry and systemic AR suppression.

3. 4-STEP PRECLINICAL TOPICAL SCREENING PIPELINE

Using the `multiverse_core.py` simulation suite, 500,000 structural derivatives were evaluated through a topical permeation and binding cascade to select clinical-grade scalp formulations.



4. PRECLINICAL TOPICAL PERMEATION DATA

Evaluation across five candidate formulations confirmed that ethosomal and hydroalcoholic solutions of **SH-14b** concentrate in the hair follicle infundibulum while maintaining minimal receiver fluid flux over 24 hours.

Candidate / Form	Vehicle Type	log P	Follicle Retention (%)	24h Systemic Flux	Topical Status
SH-1 (Wildtype)	Hydroalcoholic Solution	1.82	42.1%	14.8%	High Systemic Flux
SH-10a	Nanoemulsion Gel	2.10	68.5%	6.2%	Moderate Retention
SH-12c	Ethosomal Suspension	2.38	81.2%	3.8%	Promising Candidate
SH-14b (Lead)	Ethosomal Carrier (1%)	2.52	89.4%	1.8%	Clinical Scalp Lead
SH-15a	Lipid Nanoparticle Gel	2.75	84.0%	2.4%	Backup Lead

Key Finding: SH-14b Scalp Target Selectivity

Analogue **SH-14b** demonstrated a 12-fold increase in follicular tissue concentration compared to receiver fluid concentrations in ex vivo Franz diffusion testing, preventing systemic AR suppression while providing potent local receptor blockade.

5. IMPLEMENTATION & EXECUTION SCRIPT

The topical screening sequence is programmatically driven via the updated TopicalOptimizationEngine within multiverse_core.py:

```
# Initialize Domain 2 Topical Simulation Engine
from multiverse_core import DomainStateSpace, TopicalOptimizationEngine

topical_sim = TopicalOptimizationEngine(domain_target=2, reality_scalar=1.0)
topical_sim.set_target_parameters(
    target_logP_range=(2.2, 2.8),
    max_molecular_weight=485.0,
    max_systemic_bioavailability=0.03, # <3% target systemic flux
    min_follicular_retention_ratio=0.88
)

# Run SH-14b Topical Flux Evaluation
results = topical_sim.evaluate_topical_flux(molecule_id="SH-14b")
print(f"Follicle Retention: {results.retention_score:.2f}, Systemic Flux:
{results.systemic_flux*100:.2f}%")
```

6. TRANSLATIONAL ROADMAP FOR TOPICAL PHASE 1 STUDIES

With **SH-14b** validated for local dermal safety and high scalp tissue retention, the program advances into local GLP dermal safety testing.

- **Franz Diffusion Scale-Up:** Complete 24-hour donor skin permeation across 12 human scalp tissue samples to lock in formulation vehicle stability.
- **Primary Dermal Irritation (PDII):** Conduct 14-day repeated topical application safety studies to confirm zero skin erythema or edema.
- **GMP Vehicle Formulation:** Produce clinical-grade 1.0% SH-14b ethosomal topical solution batch lots.
- **Phase 1a Trial Design:** Author FIH scalp tolerability protocol evaluating local AR target engagement and serum systemic clearance in healthy subjects.

7. SIGN-OFF & REGULATORY APPROVAL

This report confirms completion of the preclinical topical optimization phase for SH-14b, authorizing transition to GLP dermal toxicology and Phase 1 IND filing.

Dr. Elena Rostova
Lead Computational Chemist, Domain State-Space Group

Dr. Marcus Vance
Head of Preclinical Pharmacology & Topical Therapeutics

